Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports

RATIONALE: Genotypic and histological evolution of non-small-cell lung cancer (NSCLC) into small-cell lung cancer (SCLC) has been described as a mechanism of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. However, the number of clinical cases...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Lin, Meng, Wentao, Wei, Jialiang, Zhang, Xiaofei, Tan, Zhiwei, Lu, Yunxin, Hou, Encun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969239/
https://www.ncbi.nlm.nih.gov/pubmed/33725888
http://dx.doi.org/10.1097/MD.0000000000025046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969239/
https://www.ncbi.nlm.nih.gov/pubmed/33725888
http://dx.doi.org/10.1097/MD.0000000000025046

Ejemplares similares